Moxifloxacino Cinfa (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacino Cinfa, blocks bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are essential for DNA replication and transcription. By inhibiting them, the drug prevents bacterial DNA from unwinding and resealing, leading to lethal DNA breaks and bacterial cell death.

The exact dose of Moxifloxacino Cinfa is determined by the prescribing clinician based on the specific infection, patient age, weight, renal function and local guidelines. Healthcare professionals select the appropriate strength and duration to achieve optimal therapeutic outcomes while minimizing risk.

Safety data for moxifloxacin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and after careful consideration by the prescriber.

To request Moxifloxacino Cinfa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Moxifloxacin offers a broader spectrum against atypical respiratory pathogens and has a once‑daily dosing schedule, which can improve adherence compared with some older fluoroquinolones. Its pharmacokinetic profile provides higher lung tissue concentrations, making it especially useful for respiratory infections, while sharing the class‑related safety considerations of fluoroquinolones.

Moxifloxacino Cinfa tablets should be stored at temperatures below 25 °C (77 °F). Keep them in the original blister pack or container, protect from moisture, heat and direct sunlight, and ensure the packaging remains tightly closed until use.

Moxifloxacino Cinfa is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should avoid concurrent intake of antacids containing magnesium or aluminum, as these can lower absorption. The tablet should be swallowed whole and not chewed or crushed.

Serious adverse events include tendon rupture or tendinitis, QT‑interval prolongation that may lead to cardiac arrhythmias, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, hepatic injury and peripheral neuropathy. Patients should be educated to report any sudden joint pain, palpitations, rash or persistent diarrhea promptly.

Moxifloxacino Cinfa is contraindicated in patients with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any of the tablet’s excipients. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, uncontrolled arrhythmias, or those taking medications that significantly prolong the QT interval.